Associated Papers
Novel Peptide Therapeutics Targeting the L-Type Calcium Channel Prevent Hypertrophic Cardiomyopathy by Decreasing Mitochondrial Energetics.
Er TS et al.
Jacc. Basic to Translational Science, 2025
Experimental Models of Hypertrophic Cardiomyopathy: A Systematic Review.
van den Dolder FW et al.
Jacc. Basic to Translational Science, 2025
Troponin I - a comprehensive review of its function, structure, evolution, and role in muscle diseases.
Han D et al.
Animal Cells and Systems, 2025
Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review.
Menezes Junior ADS et al.
International Journal of Molecular Sciences, 2024
Non-Canonical Localization of Cardiac Troponins: Expanding Functions or Causing Pathologies?
Arifulin EA et al.
International Journal of Molecular Sciences, 2024
Exploring contractile protein mechanisms and target medications for cardiomyopathic patients with diastolic dysfunction.
Gerber D et al.
Pediatric Discovery, 2024
New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models.
Sharma AK et al.
Scientific Reports, 2023
Genetic variants, pathophysiological pathways, and oral anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation.
Wang S et al.
Frontiers in Cardiovascular Medicine, 2023
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.
Tamargo J et al.
Expert Opinion on Investigational Drugs, 2022
Animal Models to Study Cardiac Arrhythmias.
Blackwell DJ et al.
Circulation Research, 2022
Genetic Variants Associated With Unexplained Sudden Cardiac Death in Adult White and African American Individuals.
Guo L et al.
Jama Cardiology, 2021
Preventative therapeutic approaches for hypertrophic cardiomyopathy.
Solomon T et al.
The Journal of Physiology, 2021
Electrophysiological and Structural Remodeling of the Atria in a Mouse Model of Troponin-I Mutation Linked Hypertrophic Cardiomyopathy: Implications for Atrial Fibrillation.
Lim WW et al.
International Journal of Molecular Sciences, 2021
Characterization and validation of a preventative therapy for hypertrophic cardiomyopathy in a murine model of the disease.
Viola HM et al.
Proceedings of the National Academy of Sciences of the United States of America, 2020
Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes.
Ingles J et al.
Circulation. Genomic and Precision Medicine, 2019
Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy.
Coats CJ et al.
Circulation. Genomic and Precision Medicine, 2018
Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies.
Johnstone VP et al.
Genes, 2017
The L-type Ca(2+) channel facilitates abnormal metabolic activity in the cTnI-G203S mouse model of hypertrophic cardiomyopathy.
Viola H et al.
The Journal of Physiology, 2016
Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility.
Cheng Y et al.
Archives of Biochemistry and Biophysics, 2016
Cardiac Troponin and Tropomyosin: Structural and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype.
Marques MA et al.
Frontiers in Physiology, 2016
Why Is there a Limit to the Changes in Myofilament Ca2+-Sensitivity Associated with Myopathy Causing Mutations?
Marston SB
Frontiers in Physiology, 2016
Troponin I Mutations R146G and R21C Alter Cardiac Troponin Function, Contractile Properties, and Modulation by Protein Kinase A (PKA)-mediated Phosphorylation.
Cheng Y et al.
The Journal of Biological Chemistry, 2015
A Systematic Review of Phenotypic Features Associated With Cardiac Troponin I Mutations in Hereditary Cardiomyopathies.
Mogensen J et al.
The Canadian Journal of Cardiology, 2015
A novel phosphorylation site, Serine 199, in the C-terminus of cardiac troponin I regulates calcium sensitivity and susceptibility to calpain-induced proteolysis.
Wijnker PJ et al.
Journal of Molecular and Cellular Cardiology, 2015
Targeted Next-Generation Sequencing Reveals Hot Spots and Doubly Heterozygous Mutations in Chinese Patients with Familial Cardiomyopathy.
Zhao Y et al.
Biomed Research International, 2015
Investigating the role of uncoupling of troponin I phosphorylation from changes in myofibrillar Ca(2+)-sensitivity in the pathogenesis of cardiomyopathy.
Messer AE et al.
Frontiers in Physiology, 2014
CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure.
Tsoutsman T et al.
Journal of Molecular and Cellular Cardiology, 2013
Structural and kinetic effects of hypertrophic cardiomyopathy related mutations R146G/Q and R163W on the regulatory switching activity of rat cardiac troponin I.
Zhou Z et al.
Archives of Biochemistry and Biophysics, 2013
Inherited cardiomyopathies caused by troponin mutations.
Lu QW et al.
Journal of Geriatric Cardiology : Jgc, 2013
Familial hypertrophic cardiomyopathy related E180G mutation increases flexibility of human cardiac α-tropomyosin.
Loong CK et al.
Febs Letters, 2012
Myocardial contractile and metabolic properties of familial hypertrophic cardiomyopathy caused by cardiac troponin I gene mutations: a simulation study.
Wu B et al.
Experimental Physiology, 2012
Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure.
Bagnall RD et al.
Plos One, 2012
Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy.
van den Wijngaard A et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 2011
Opposing actions of extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) in regulating microtubule stabilization during cardiac hypertrophy.
Ng DC et al.
The Journal of Biological Chemistry, 2011
Genetic screening and double mutation in Japanese patients with hypertrophic cardiomyopathy.
Kubo T et al.
Circulation Journal : Official Journal of the Japanese Circulation Society, 2011
Facilitated cross-bridge interactions with thin filaments by familial hypertrophic cardiomyopathy mutations in α-tropomyosin.
Wang F et al.
Journal of Biomedicine & Biotechnology, 2011
Analysis of the sarcomere protein gene mutation on cardiomyopathy - Mutations in the cardiac troponin I gene.
Murakami C et al.
Legal Medicine (tokyo, Japan), 2010
Differential protein expression profiling of myocardial tissue in a mouse model of hypertrophic cardiomyopathy.
Lam L et al.
Journal of Molecular and Cellular Cardiology, 2010
Malignant and benign mutations in familial cardiomyopathies: insights into mutations linked to complex cardiovascular phenotypes.
Xu Q et al.
Journal of Molecular and Cellular Cardiology, 2010
The C terminus of cardiac troponin I stabilizes the Ca2+-activated state of tropomyosin on actin filaments.
Galińska A et al.
Circulation Research, 2010
Combinatorial effects of double cardiomyopathy mutant alleles in rodent myocytes: a predictive cellular model of myofilament dysregulation in disease.
Davis J et al.
Plos One, 2010
Defective dynamic properties of human cardiac troponin mutations.
Lassalle MW
Bioscience, Biotechnology, and Biochemistry, 2010
Role of animal models in HCM research.
Shephard R et al.
Journal of Cardiovascular Translational Research, 2009
Functional analysis of a unique troponin c mutation, GLY159ASP, that causes familial dilated cardiomyopathy, studied in explanted heart muscle.
Dyer EC et al.
Circulation. Heart Failure, 2009
Multiple mutations in genetic cardiovascular disease: a marker of disease severity?
Kelly M et al.
Circulation. Cardiovascular Genetics, 2009
Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure.
Tsoutsman T et al.
Clinical and Experimental Pharmacology & Physiology, 2008
Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice.
Wen Y et al.
The Journal of Biological Chemistry, 2008
Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI.
Du J et al.
American Journal of Physiology. Heart and Circulatory Physiology, 2008
Troponin: regulatory function and disorders.
Ohtsuki I et al.
Biochemical and Biophysical Research Communications, 2008
Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy.
Tsoutsman T et al.
Circulation, 2008